Latest Health News

Peppermint Innovation Limited posted a $2.4 million net loss for FY26 as it shifted from platform development to commercial execution in the Philippines, achieving key regulatory milestones and securing strategic investment.

Mayfield Childcare’s HY26 results reveal a 6% revenue decline and deepening statutory loss, offset by operational improvements and strategic restructuring.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

AMCIL posted a $6.9 million profit for FY2026 while its portfolio returned negative 10%, underperforming the ASX 200. The company cut dividends to 4.0 cents fully franked, reshuffled holdings, and welcomed Alison Gibson as new CEO.

Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.

Gratifii Limited trimmed its net loss to $7.56 million in FY26, supported by a full-year contribution from Club Connect and a $5 million strategic investment in Marketplacer. Despite a 2.5% revenue dip, the company advanced its loyalty platform through acquisitions and AI integration.

Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.

Kingsgate Consolidated delivered a record FY2026 net profit of $278 million, driven by strong gold and silver output at Chatree and a $68.6 million impairment reversal at the Nueva Esperanza project, while declaring a 10 cent final dividend.

Vection Technologies (ASX:VR1) achieved a major earnings inflection in FY26 with adjusted EBITDA soaring 596% to $3.8 million and generating positive operating cash flow for the first time, underpinned by dual commercial platforms scaling rapidly.

Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.

PeopleIN Limited reversed its earnings decline in FY26, driven by a 74.8% surge in its Engineering, Trades and Labour division amid Queensland’s booming infrastructure projects. The company’s sharper portfolio focus and strengthened balance sheet set the stage for further growth.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.